Cutler Group LP Halozyme Therapeutics, Inc. Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 26, 2021	SELL	$39.51 - $51.45 $217,305 - $282,975	-5,500 Closed	0 $0
Q4 2020 Jan 21, 2021	BUY	$25.81 - $43.62 $141,955 - $239,910	5,500 New	5,500 $234,000
Q1 2020 May 07, 2020	SELL	$13.9 - $21.83 $5,240 - $8,229	-377 Closed	0 $0
Q4 2019 Feb 06, 2020	SELL	$14.93 - $19.53 $41,804 - $54,684	-2,800 Reduced 88.13%	377 $6,000
Q3 2019 Oct 28, 2019	SELL	$15.2 - $17.69 $1,520 - $1,769	-100 Reduced 3.05%	3,177 $49,000
Q2 2019 Aug 09, 2019	BUY	$14.75 - $17.26 $42,775 - $50,054	2,900 Added 769.23%	3,277 $56,000
Q1 2019 May 10, 2019	SELL	$13.94 - $17.58 $4,182 - $5,273	-300 Reduced 44.31%	377 $6,000
Q2 2018 Aug 10, 2018	SELL	$16.87 - $20.3 $3,374 - $4,060	-200 Reduced 22.81%	677 $11,000
Q1 2018 May 11, 2018	BUY	$17.06 - $21.2 $13,255 - $16,472	777 Added 777.0%	877 $17,000
Q4 2017 Jan 17, 2018	SELL	$16.75 - $20.8 $27,704 - $34,403	-1,654 Reduced 94.3%	100 $2,000
Q3 2017 Oct 17, 2017	BUY	$11.76 - $17.4 $20,627 - $30,519	1,754	1,754 $30,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.